Highlights of This Issue 1415

REVIEW

1417 Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside
Justin Korfhage and David B. Lombard

1429 Evaluation of Tumor Cell–Tumor Microenvironment Component Interactions as Potential Predictors of Patient Response to Napabucasin
An-Yun Chang, Eric Hsu, Jaimin Patel, Yiqun Li, Minjie Zhang, Haruhisa Iguchi, and Harry A. Rogoff

CANCER GENES AND NETWORKS

1435 Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
Xiaomeng Zhang, Tian Zhong Tang, Ismael A. Vergara, Youfang Zhang, Pacman Szeto, Lie Yang, Christopher Mintoff, Andrew Colebatch, Lachlan McIntosh, Katrina A. Mitchell, Evangele Shaw, Helen Rizos, Georgina V. Long, Nicholas Hayward, Grant A. McArthur, Anthony T. Papenfuss, Kieran F. Harvey, and Mark Shackleton

1450 The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells
Jun Gui, Kanstantsin V. Katlinski, Constantinos Koumenis, J. Alan Diehl, and Serge Y. Fuchs

1459 TP53 Mutation by CRISPR System Enhances the Malignant Potential of Colon Cancer
Sho Watanabe, Kichiro Tsuchiya, Ryu Nishimura, Tomaoki Shirasaki, Nobuhiro Katsukura, Shuji Hibiya, Ryuichi Okamoto, Tetsuya Nakamura, and Mamoru Watanabe

1468 The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice
Lauren J. Tracey, Travis Brooke-Bisschop, Pascal W.T.C. Jansen, Eric I. Campos, Michiel Vermeulen, and Monica J. Justice

1480 Paracrine Interaction of Cancer Stem Cell Populations Is Regulated by the Senescence-Associated Secretory Phenotype (SASP)
Angelica M. Lagunas, Marybeth Francis, Nisha B. Maniar, Gergana Nikolova, Jianchun Wu, and David L. Crowe

CANCER ”-OMICS”

1493 Characterization of HCC Mouse Models: Towards an Etiology-Oriented Subtyping Approach
Juliane Friemel, Lukas Frick, Kristian Unger, Michele Egger, Rossella Parrotta, Yannick T. Boge, Arlind Adili, Michael Karin, Tom Luedde, Mathias Heikenwalder, and Achim Weber

CELL FATE DECISIONS

1503 GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer

1519 Hyperphosphorylation of CDH1 in Glioblastoma Cancer Stem Cells Attenuates APC/CCDH1/CDC20 Activity and Pharmacologic Inhibition of APC/CCDH1/CDC20 Compromises Viability
Kuntal De, Treg M. Grubb, Abigail A. Zalenski, Kaya E. Pfaff, Debjani Pal, Shubhra Majumder, Matthew K. Summers, and Monica Venere

METABOLISM

1531 Adaptation to HIF1α Deletion in Hypoxic Cancer Cells by Upregulation of GLUT14 and Creatine Metabolism
Alessandro Valili, Matteo Morotti, Christos E. Zois, Patrick K. Albers, Tomoyoshi Soga, Katharina Feldinger, Roman Fischer, Martin Frejno, Alan McIntyre, Esther Bridges, Syed Haider, Francesca M. Buffa, Dilair Baban, Miguel Rodriguez, Oscar Yanes, Hannah J. Whittington, Hannah A. Lake, Sevasti Zervou, Craig A. Lygate, Benedikt M. Kessler, and Adrian L. Harris
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>1545</td>
<td>Optical Imaging of Glucose Uptake and Mitochondrial Membrane Potential to Characterize Her2 Breast Tumor Metabolic Phenotypes</td>
<td>Megan C. Madonna, Douglas B. Fox, Brian T. Crouch, Jihong Lee, Caigang Zhu, Amy F. Martinez, James V. Alvarez, and Nirmala Ramanujam</td>
</tr>
<tr>
<td>1556</td>
<td>Dual TGFβ/BMP Pathway Inhibition Enables Expansion and Characterization of Multiple Epithelial Cell Types of the Normal and Cancerous Breast</td>
<td>Mayuri Prasad, Brijesh Kumar, Poornima Bhat-Nakshatri, Manjushree Anjanappa, George Sandusky, Kathy D. Miller, Anna Maria Storniolo, and Harikrishna Nakshatri</td>
</tr>
<tr>
<td>1571</td>
<td>p21CIP1 Promotes Mammary Cancer–Initiating Cells via Activation of Wnt/TCF1/CyclinD1 Signaling</td>
<td>Outhiriaradjou Benard, Xia Qian, Huizhi Liang, Zuen Ren, Kimita Suyama, Larry Norton, and Rachel B. Hazan</td>
</tr>
</tbody>
</table>

### About the Cover

Hippo pathway signaling through hyperactivated YAP has been shown to promote aggressive phenotypes in uveal melanoma, but its role in cutaneous melanoma is poorly understood. In this issue, Zhang and colleagues demonstrate that YAP is upregulated and hyperactivated in most premalignant melanocytic nevi and malignant melanoma lesions, and it presents a potential therapeutic target in a subset of melanoma patients. Moreover, the authors provide clinical evidence for the first known activating YAP mutations in human cancer. See the article beginning on page 1435 for more information.

The cover depicts co-immunofluorescence staining of a clinical case of cutaneous melanoma (red, Melan-A; green, YAP1; blue, nuclei stained with DAPI).